CN102895428B - 一种治疗犬猫尿结石的中药组合物 - Google Patents
一种治疗犬猫尿结石的中药组合物 Download PDFInfo
- Publication number
- CN102895428B CN102895428B CN201210417773.0A CN201210417773A CN102895428B CN 102895428 B CN102895428 B CN 102895428B CN 201210417773 A CN201210417773 A CN 201210417773A CN 102895428 B CN102895428 B CN 102895428B
- Authority
- CN
- China
- Prior art keywords
- parts
- calculus
- dog
- chinese medicine
- cat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000009911 Urinary Calculi Diseases 0.000 title claims abstract description 21
- 241000282326 Felis catus Species 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title abstract description 20
- 206010007027 Calculus urinary Diseases 0.000 title abstract description 4
- 238000000034 method Methods 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 241000282465 Canis Species 0.000 claims description 10
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000737253 Lygodium japonicum Species 0.000 abstract 1
- 241001571764 Lysimachia christinae Species 0.000 abstract 1
- 241001648835 Polygonum cuspidatum Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000010446 mirabilite Substances 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 30
- 210000002700 urine Anatomy 0.000 description 23
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- 210000003708 urethra Anatomy 0.000 description 8
- 239000004575 stone Substances 0.000 description 7
- 208000019206 urinary tract infection Diseases 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 208000019932 Aciduria Diseases 0.000 description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 206010030302 Oliguria Diseases 0.000 description 3
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 201000003126 Anuria Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical class [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
- 229940099500 cystamine Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011778 Cystinuria Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 208000004608 Ureteral Obstruction Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- FOFYPMPFTYORPL-UHFFFAOYSA-N azanium;2,8-dioxo-7,9-dihydro-3h-purin-6-olate Chemical compound N.N1C(=O)NC(=O)C2=C1NC(=O)N2 FOFYPMPFTYORPL-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000021375 calcium rich food Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗犬猫尿结石的中药组合物,其特征为按重量份数计由如下组分制成:海金沙5-500份、金钱草5-500份、芒硝5-500份、虎杖5-500份、牛膝5-300份、蒲黄5-250份、甘草5-250份。本发明方案可以有效治愈犬猫尿结石,疗效好的同时治疗手段简便、治疗痛苦小。
Description
技术领域
本发明属于中兽药领域,尤其是涉及一种使用中兽药治疗犬猫尿结石的治疗方法。
背景技术
尿液中的可溶性盐过饱和时,盐会沉淀形成结晶,如果这些结晶不能被及时排泄出体外,它们可能聚集形成固态,称为结石。尿石病指体内(肾脏、尿道、膀胱或输尿管)有尿结石存在,引发尿路粘膜发炎、出血和尿路阻塞,临床上以排尿障碍,肾性腹痛和血尿、尿频、尿淋漓等为特征。犬猫尿结石是一种犬猫最常见的泌尿器官疾病。泌尿器官炎症合并尿液酸碱度改变,红细胞、白细胞、上皮细胞、细菌、尿管型形成结石核心,尿液深缩,单调的食物,维生素A缺乏,先天性代谢异常,以及猫萼状病毒感染等可导致犬猫尿结石。
大部分犬的尿结石见于膀胱和尿道内。最常见的犬结石是鸟粪石(即磷酸铵镁),此外还有草酸钙、硅酸盐、胱氨酸盐和混合型的结石。尿道感染是犬形成鸟粪石的主要原因。能够产生脲酶的细菌可将尿素分解为氨水和二氧化碳。氨水可水解成铵离子和羟基,使尿液呈碱性,从而降低鸟粪石的溶解度形成结石。同时细菌性结石还增加尿液内有机碎片的形成,而后者又可再孕育结晶产生。对于猫,尽管没有泌尿感染到尿液中(UTI),但也可能形成鸟粪石。
草酸钙结晶最常见于暂时性餐后高钙血症和高钙尿症的犬。大多数感染犬,甲状旁腺激素浓度低于正常水平。在肾小管对钙吸收的缺乏、甲状旁腺功能亢进初期、淋巴瘤、维生素D中毒、尿枸橼酸盐浓度降低或饮食中草酸盐浓度高等情况下,犬也可能发生尿结石,但几率较低。尿结石很少伴发UTI。酸性尿有助于草酸盐结晶的形成。
腹部结石通常由内源性嘌呤核苷酸和饮食中的核苷酸代谢产物尿酸铵组成。达尔马西亚犬由于缺乏肝脏转运尿酸的功能,导致尿囊素形成减少和尿中尿酸排泄的增加。达尔马西亚犬也常发生远端和近端肾小管对尿酸分泌功能的降低,所以这一品种的犬易形成结石。此外,硅酸盐结石的形成可能与饮食中过量的硅酸盐、硅酸或镁盐有关。雄性德国牧羊犬和老龄英国牧羊犬形成硅酸盐性尿结石的几率较高。胱氨酸尿结石常可由遗传性肾小管运输功能障碍引起,常发生于酸性尿中。
根据其发生机理,尿结石的主要成分有:磷酸盐、草酸盐、碳酸盐、胱胺酸盐和尿酸。以磷酸盐结石的发生率最高(超过60%),其次是草酸盐结石(3~30%)和碳酸盐结石。胱胺酸盐和尿酸盐结石的发生率最低(0~20%)。以晶体成分为分类依据,犬猫尿结石可分为以下几种:
1.草酸盐结石
棕褐色,质紧硬,表面粗糙有刺,呈桑椹形,切面呈环形层状。容易损伤尿路粘膜引起血尿,在碱性尿内形成,可以是单纯的草酸钙结石,但多数为草酸钙和磷酸钙混合性结石。常发生于迷你髯狗、西藏拉萨犬、约克夏犬等,雄性青年犬、老年犬多发。
2.鸟粪石结石
表面光滑或有颗粒,质硬或松脆易碎。切面常见有核心(为细菌或脱落上皮等),呈同心性层状结构。在碱性尿中形成,常与碳酸盐混合。多发生于迷你髯狗、长卷毛白狮子犬。垂耳可卡犬等,雌性犬比雄性犬多发,已发生泌尿道感染。治疗时应维持尿液PH<6.5,BUN<10mg/dL,尿比重<1.020。为预防该结石的发生,应监视尿液pH值和尿沉积物,并尽快正确地消除感染。
3.尿酸盐结石
黄色或褐色,表面光滑,质硬,圆或卵圆形,常形成多数小结石,在酸性尿内形成。尿酸结石可为单纯性或与草酸钙、磷酸钙等形成混合结石,单纯尿酸结石X线可透过常不显影,混合结石X线不透过可显影。尿酸盐结石多发生于斑点狗、英国斗牛犬,其余多为由门静脉分流特征的犬,即约克夏犬、髯犬、京巴犬、西藏拉萨犬。
4.胱氨酸结石
黄白色、光滑、外观蜡样,X线能透过,不易显影,形成于酸性尿中。常发生于德国猎犬、英国斗牛犬等。
5.硅酸盐结石
常发生于德国牧羊犬、金毛猎犬、拉布拉多犬等。常手术摘除治疗。
根据尿频、尿痛等排尿障碍及血尿等临床特征,应及时对本病进行诊治。膀胱结石和尿道结石可经探诊和触诊发现结石部位。X射线检查及超声探查可确定结石的部位和数量。治疗时应加强护理,及时排除结石,控制感染。通常采取的治疗方法为排除结石、尿路消炎、支持疗法等措施进行治疗。手术是排石的一种手段,尿路冲洗等保守疗法也在治疗犬猫结石时经常使用。一般据情况采取不同排石方法,如果结石较小呈细沙样,可采取尿道逆行冲洗排出结石:尿道插入尿导管,然后向尿道管注入大量生理盐水,当压力达到一定程度时突然放开并同时按压腹部来冲出小结石,可反复几次直到冲洗液内无异物为止;如结石稍大,冲洗不出来,可先用激光、超声波等击碎结石,或使用排石冲剂排出结石;如结石较大,特别是膀胱结石,则要及早手术取出结石。
上述排石方法虽然有较好的疗效,但造成犬猫的治疗痛苦大,且操作实施不方便。
发明内容
为了克服上述不足,本发明提供了一种针对犬猫尿结石的疗效好、治疗痛苦小的中药治疗方法。
本发明提供的具体技术方案为:一种犬猫尿结石的中药治疗方法,包括如下步骤:
1)将中药组合物混合,加水煎煮半小时,按重量份数计,中药组合物与水的比例为1:4-15,煎煮去渣得药液;其中所述中药组合物由如下中药原料组成:海金沙、金钱草、芒硝、虎杖、牛膝、蒲黄、甘草;
2)将患病猫犬根据大小用10~30ml药液强行灌服,1次/天,连服5天。
其中,上述中药组合物按重量份数计为:海金沙5-500份、金钱草5-500份、芒硝5-500份、虎杖5-500份、牛膝5-300份、蒲黄5-250份、甘草5-250份。
进一步地,上述中药组合物按重量份数计为:海金沙150份、金钱草200份、芒硝150份、虎杖200份、牛膝150份、蒲黄150份、甘草100份。
尿结石是由于尿路感染或代谢异常等引起尿中盐类沉积在肾盂、膀胱等形成结石,引起输尿管或尿道发生阻塞性疾病。根据结石阻塞部位可分为肾结石、输尿管结石、膀胱结石、尿道结石。犬猫多由于长期饲喂高钙食物引起代谢异常或长时间服用易在尿中析出药物而发病。一般其症状体现为:
(1)尿频、尿少,频做排尿姿势,每次只排少量尿液或无尿,排尿痛苦,有时排红色血尿。
(2)膀胱积尿、腹部膨大,触诊腹部有痛感,有的可摸到结石硬块。
(3)长期闭尿可引起尿毒症,使病情加重,症状明显。沉郁不食、呕吐脱水、巩膜充血;呼出气体带有氨气味,血中尿素氮、肌酸酐含量增高;膀胱膨大、麻痹,严重时失去弹性甚至破裂。
诊断:根据主要症状如尿频、尿少或无尿,排尿困难和痛苦,膀胱积尿等做出初步诊断。要确诊可做X光检查,可检出结石部位、大小、多少等。
该病症状与尿路感染相似,都有尿频、尿少、排尿困难和痛苦等症状,所以诊断时要注意鉴别。两者最大区别是尿结石可通过X光检查出结石部位、大小等。
对于发病初期的犬。采用本发明方案3-5天即可见效,对患病较严重的犬,一般1-2周后可见明显效果,治疗3-5周痊愈。
本发明方案可以有效治愈犬猫尿结石,疗效好的同时治疗手段简便、治疗痛苦小。
当然虽然结石的治疗至关重要,但饲养管理也是结石治愈和防止结石复发的保证。应改善饲养,减少富含钙质的食物,大量饮水,以便形成大量稀释尿,借以冲淡尿液晶体浓度,减少析出并防止沉淀。
具体实施方式
下面通过具体实施例对本发明作进一步详述,以下实施例只是描述性的,不是限定性的,不能以此限定本发明的保护范围。
实施例1
一种犬猫尿结石的中药治疗方法:将下述中药原料海金沙150g、金钱草200g、芒硝150g、虎杖200g、牛膝150g、蒲黄150g、甘草100g混合,加水4000ml,煎至2500ml,去渣得药液,将病重猫犬用20ml强行灌服,1次/天,连服5天。
以上对本发明的较佳实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
Claims (2)
1.一种治疗犬猫尿结石的中药组合物,其特征为按重量份数计由如下组分制成:海金沙5-500份、金钱草5-500份、芒硝5-500份、虎杖5-500份、牛膝5-300份、蒲黄5-250份、甘草5-250份。
2.如权利要求1所述中药组合物,其特征为按重量份数计由如下组分制成:海金沙150份、金钱草200份、芒硝150份、虎杖200份、牛膝150份、蒲黄150份、甘草100份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210417773.0A CN102895428B (zh) | 2012-10-26 | 2012-10-26 | 一种治疗犬猫尿结石的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210417773.0A CN102895428B (zh) | 2012-10-26 | 2012-10-26 | 一种治疗犬猫尿结石的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102895428A CN102895428A (zh) | 2013-01-30 |
CN102895428B true CN102895428B (zh) | 2015-06-17 |
Family
ID=47568114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210417773.0A Active CN102895428B (zh) | 2012-10-26 | 2012-10-26 | 一种治疗犬猫尿结石的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102895428B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115006465B (zh) * | 2022-07-13 | 2023-06-13 | 四川省畜牧科学研究院 | 治疗动物尿结石的冲洗液及其制备方法 |
-
2012
- 2012-10-26 CN CN201210417773.0A patent/CN102895428B/zh active Active
Non-Patent Citations (1)
Title |
---|
犬尿结石的病因及诊治进展;王哲慈;《中国动物保健》;20101130;第2010年卷(第11期);54-57 * |
Also Published As
Publication number | Publication date |
---|---|
CN102895428A (zh) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Makhdoomi et al. | Obstructive urolithiasis in ruminants-A review. | |
Ewoldt et al. | Short‐and long‐term outcome and factors predicting survival after surgical tube cystostomy for treatment of obstructive urolithiasis in small ruminants | |
CN102895428B (zh) | 一种治疗犬猫尿结石的中药组合物 | |
Defarges et al. | Urolithiasis in small animals | |
CN101698016B (zh) | 一种治疗牛瓣胃阻塞的组合物及其制备方法 | |
CN102000142A (zh) | 一种治疗泌尿系结石的中药组合物 | |
CN105434915A (zh) | 一种用于治疗犬猫泌尿道结石的药物组合物及其制备方法 | |
CN104083659A (zh) | 一种治疗结石的中药制剂 | |
CN1985935A (zh) | 治疗痛风病的蜂黄痛风胶囊及其制备方法 | |
CN104548016A (zh) | 一种中药组合物在制备治疗高尿酸血症药物中的用途 | |
CN108478675B (zh) | 预防舍饲绵羊尿结石复方中药组合物 | |
CN106492075A (zh) | 一种治疗前列腺增生的中药组合物及其制备方法 | |
CN114375910A (zh) | 一种用于构建尿石症猫疾病模型的组合物 | |
CN108079210B (zh) | 用于治疗宠物犬磷酸铵镁尿结石的膀胱灌注液 | |
Li et al. | Progress on the causes and current status of canine urolithiasis | |
LU508584B1 (en) | Medicinal powder for treating gout and preparation method thereof | |
CN104667026A (zh) | 一种治疗胃肠积热型便秘的中药组合物 | |
CN110038048B (zh) | 一种用于辅助治疗马腺疫的中药组合物 | |
Glenn | Elvis’s Rock-a-Billy Goat Blues | |
CN115006465B (zh) | 治疗动物尿结石的冲洗液及其制备方法 | |
Rizkyansyah et al. | Pediatric Bladder Stone in Secondary Hospital Care Setting: A Case Report | |
CN101732624A (zh) | 输尿管结石的治疗配方及其制作方法 | |
CN113144007B (zh) | 一种治疗高尿酸血症的中药组合物及制备方法 | |
CN101024054A (zh) | 一种内服治疗腺性膀胱炎的中药组合物 | |
Sudarmi et al. | AYURVEDIC MANAGEMENT OF MUTRASHMARI–A REVIEW ARTICLE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |